Skip to content

Author

Reyadh Jassem

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

VEGFR-2 as a druggable target: recent advances (2025) in the development of five-membered heterocyclic anticancer agents.

This comprehensive review systematically examines recent advances in the rational design, synthesis, and biological evaluation of five-membered heterocyclic scaffolds, thiadiazol, oxazole, thiazole, thiazole, and pyrrole, as well as pyrazole and imidazole-based inhibitors as novel VEGFR-2 inhibitors.

Mohamed M. Khalifa, Ibtehal Naseer Salman, Reyadh Jassem · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.